Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis.

MLA

Garate, David, et al. “Risk of Malignancy Associated with Use of Dupilumab versus Other Treatments in Atopic Dermatitis Patients: A National Database Analysis.” The Journal of Allergy and Clinical Immunology. In Practice, Nov. 2024. EBSCOhost, https://doi.org/10.1016/j.jaip.2024.11.015.

APA

Garate, D., Thang, C. J., Chang, C. T., Owji, S., Murphy, T. L., Golovko, G., Da Rosa, J. C., Guttman-Yassky, E., Wilkerson, M. G., & Gulati, N. (2024). Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis. The Journal of Allergy and Clinical Immunology. In Practice. https://doi.org/10.1016/j.jaip.2024.11.015

Chicago

Garate, David, Christopher J Thang, Crystal T Chang, Shayan Owji, Trevor L Murphy, George Golovko, Joel Correa Da Rosa, Emma Guttman-Yassky, Michael G Wilkerson, and Nicholas Gulati. 2024. “Risk of Malignancy Associated with Use of Dupilumab versus Other Treatments in Atopic Dermatitis Patients: A National Database Analysis.” The Journal of Allergy and Clinical Immunology. In Practice, November. doi:10.1016/j.jaip.2024.11.015.